Doxy.me vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
1M+ clinicians 150+ countries; 250K active providers; $50.2M revenue; acquired Telehealth.org/TeleMental Health Institute 2025; TIME HealthTech 2025; Ventures fund; telemedicine leader
About
Doxy.me was founded in 2013 by Brandon Welch in Hawaii with a mission to make telehealth accessible to every clinician and patient, regardless of technical sophistication or budget. The platform was built as a browser-based, zero-download video conferencing solution designed specifically for healthcare — requiring no app installation for patients and offering HIPAA-compliant video sessions out of the box. This simplicity-first approach drove grassroots adoption among solo practitioners and small clinics.\n\nDoxy.me's platform provides HIPAA-compliant video visits, virtual waiting rooms, patient intake forms, group rooms, and integrations with major EHR and practice management systems. Its free tier has been instrumental in driving adoption among independent clinicians who need compliant telehealth without enterprise procurement cycles. Premium tiers add advanced features including custom branding, staff accounts, and analytics. In 2025, Doxy.me acquired Telehealth.org and the TeleMental Health Institute, expanding its educational resources and professional training offerings.\n\nDoxy.me has grown to serve 1M+ clinicians across 150+ countries, with 250,000 active providers using the platform regularly. The company reported $50.2M in annual revenue and was recognized on TIME's HealthTech 2025 list. Its combination of clinical accessibility, global reach, and a freemium model that converts at scale positions Doxy.me as a foundational layer of the global telehealth infrastructure — particularly for solo and small-group practices that larger enterprise platforms overlook.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.